Doxazosin Tablet
Product Images NDC 71205-690

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 71205-690). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

71205-690-30 (Doxazosin 4mg 100)

71205-690-30 (Doxazosin 4mg 100)
This is the packaging information for Doxazosin tablets, with a strength of 4mg, and a quantity of 30 tablets in each package. The tablets are round, uncoated, and are of a cream to yellow color. Each tablet is debossed with "C4" on one side and has a break line on the other side. The product is packaged and distributed by Proficient Rx in Thousand Oaks, CA. The manufacturer of the tablets is Intas Pharmaceuticals in India. The tablets should be stored at a temperature between 20°-25°C and should be kept out of reach of children. The lot number is 00000 and the expiration date is 000000.*
FDA Label Image

Table 1 (Doxazosin Fig1)

Table 1 (Doxazosin Fig1)
The text describes a summary table presenting effectiveness data from placebo-controlled trials. The table includes information on maximum flow rate, symptom score, baseline change, and the number of participants in each study. There are three different studies included in the table, each with different dosages of medication and varying lengths of time. Study 2 used a fixed dose for 14 weeks and collected data using a Modified Boyarsiy Questionnaire. The text also notes that the endpoint changed and provides information on the 8 mg dosage of doxazosin. Not enough information is available to determine the specifics of the medication being studied or any results of the trials.*
FDA Label Image

Figure 1 – Study 1 (Doxazosin Fig2)

Figure 1 – Study 1 (Doxazosin Fig2)
The text provides data on mean increase in maximum urinary flow rate and mean change in total symptom score from baseline. The treatment duration is indicated in weeks. The data includes placebo and Doxazosin Titration for a maximum of 8 mg. The text also shows statistical significance comparisons between the results and the baseline or placebo.*
FDA Label Image

Chemical Structure (Doxazosin Str)

Chemical Structure (Doxazosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.